News
Freshfields Advises SERB Pharmaceuticals on Purchase of RSDL® (Reactive Skin Decontamination Lotion) Kit from Emergent BioSolutions Inc.
Freshfields advises Charterhouse portfolio company, SERB Pharmaceuticals on its acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. (NYSE: EBS). RSDL® is a medical device produced as a kit that removes or neutralizes chemical warfare agents from the skin. Freshfields advised on all aspects of this product carveout, including on supply chain related milestones and on all complex transitional and long-term services arrangements as well.
The Freshfields team was led by M&A partner Paul Humphreys and life sciences counsel Jeff Jay. The team included M&A senior associate Ted Haxby and associates Connor Smith and Patrick Boldea, as well as life sciences associates Dylan O’Connor, Jake Silvers and Laura Zhu. Employment and benefits advice was provided by partner Nicole Foster and associate Lina Zhu. Antibribery and sanctions advice was provided by partner Stephanie Brown-Cripps and associate Seve Kale. Restructuring advice was provided by partner Madlyn Primoff and associate Ellen Lawrence.
About Freshfields Bruckhaus Deringer LLP
Freshfields Bruckhaus Deringer is a global law firm with a long-standing track record of successfully supporting the world's leading national and multinational corporations, financial institutions and governments on groundbreaking and business-critical mandates. Our 2,800-plus lawyers and other legal professionals deliver results worldwide through our own offices and alongside leading local firms. Our commitment, local and multinational expertise, and business know-how means our clients rely on us when it matters most.
Freshfields holds eight global Band 1 rankings from Chambers across antitrust, corporate/M&A, litigation, international arbitration, employee benefits, tax, public international law, and crisis management. For more information visit our home page.
